Latest Breaking News On - ப்ரோடீந் சிகிச்சை - Page 1 : comparemela.com
Share this article
Share this article
ResearchAndMarkets.com s offering.
The IVD reagents market is expected to grow at a CAGR of 7% from 2020 to 2027 to reach $77.6 billion by 2027.
The growth in the IVD reagents market is mainly attributed to the factors such as increasing global prevalence of acute and chronic infectious diseases coupled with rising geriatric population, increasing adoption of flow cytometry techniques in research and academia, increase in funding for research activities, and rising proteomics and genomics research studies. Moreover, the growing demand for protein therapeutics and personalized medicines and emerging economies offer significant growth opportunities for the players operating in this market.
China
Germany
United-states
Canada
Dublin
Ireland
France
America
Europe-ro
Asia-pacific-ro
Laura-wood
Technology-immunoassay
Top Key Players Profiled in this report are:
AbbVie , Amgen , F. Hoffmann-La Roche , Johnson & Johnson , Merck , Novo Nordisk , Anhui Anke Biotechnology , AstraZeneca , Baxter International , Biocon , Biodel , BioGenomics , Biopartners , Boehringer Ingelheim , Bristol-Myers Squibb , Celltrion , Chugai Pharmaceutical , Diamyd Medical , Diasome Pharmaceuticals , DiaVacs , Dynavax Technologies , Eli Lilly , Ferring Pharmaceuticals , Generex Biotechnology , GeneScience Pharmaceuticals , Hualan Biological Engineering , Intas Pharmaceuticals , Ipsen , JCR Pharmaceuticals , Kyowa Hakko Kirin.
Various factors are responsible for the market’s growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Protein Therapeutics market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The in
Malaysia
Australia
Japan
Philippines
Brazil
China
Vietnam
Republic-of
Indonesia
Canada
Mexico
Germany